Navigation Links
WorldHeart Receives IRB Approval at First Center in the Levacor(TM) VAD BTT Clinical Trial
Date:10/15/2009

SALT LAKE CITY, Oct. 15 /PRNewswire-FirstCall/ -- ("WorldHeart"; Nasdaq: WHRT) - World Heart Corporation (WorldHeart) announced today that the Levacor Ventricular Assist Device (VAD) Bridge-to-Transplant (BTT) Study has been approved by the Institutional Review Board (IRB) at INTEGRIS Baptist Medical Center in Oklahoma City. On-site clinical and technical training has been conducted, formally qualifying this center as the first for the Levacor Study.

Dr. Douglas Horstmanshof is the Program Director of the INTEGRIS Baptist Heart Failure Institute and the center's Principal Investigator for the Levacor trial. Dr. James W. Long is the Study's Co-Investigator and the Director of INTEGRIS Advanced Cardiac Care, which is the only ventricular assist device program in Oklahoma. Both clinicians have long been active in transplant and circulatory support therapies, and Dr. Horstmanshof notes that "we are excited to participate in the Levacor Study and to bring the potential benefits of this unique fourth-generation VAD technology to our heart failure patients."

As previously announced, WorldHeart has conditional approval from the FDA for the Levacor BTT Study for ten initial study sites. Mr. J. Alex Martin, WorldHeart President and CEO said that "we are eager to move forward into the clinical setting and are extremely pleased to announce INTEGRIS Baptist's qualification status. We also continue to work closely with other participating hospitals as their IRBs review the Study protocol."

The Levacor VAD is the only bearingless, fully magnetically levitated, implantable centrifugal pump to enter clinical trial. Mr. Jal S. Jassawalla, WorldHeart's Executive Vice President and Chief Technology Officer, commented "our objective is to demonstrate that this newer-generation technology will minimize complications and provide long-lasting, dependable, performance. We look forward to working with leading clinicians to demonstrate Levacor's safety and efficacy."

About World Heart Corporation

WorldHeart is a developer of mechanical circulatory support systems in Salt Lake City, Utah with additional facilities in Oakland, California, USA and Herkenbosch, The Netherlands. WorldHeart's registered office is in Ottawa, Ontario, Canada.

Any forward-looking statements in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include all statements relating to the advancement of WorldHeart's clinical development programs, the potential clinical benefits of the Levacor VAD, and the growth of WorldHeart's overall business, as well as other statements that can be identified by the use of forward-looking language, such as "believes," "feels," "expects," "may," "will," "should," "seeks," "plans," "anticipates," or "intends" or the negative of those terms, or by discussions of strategy or intentions. Investors are cautioned that all forward-looking statements involve risk and uncertainties, including without limitation: WorldHeart's need for additional capital in the future; risks in product development, regulatory approvals and market acceptance of and demand for WorldHeart's products; successful completion of the Levacor VAD Bridge-to-Transplant Study; and other risks detailed in WorldHeart's filings with the U.S. Securities and Exchange Commission, including without limitation its Annual Report on Form 10-K for the year ended December 31, 2008 and its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2009 and June 30, 2009.

www.worldheart.com

SOURCE World Heart Corporation


'/>"/>
SOURCE World Heart Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. WorldHeart Receives US Clinical Study Approval for the Levacor(TM) VAD
2. WorldHeart Announces Further Milestone in Miniaturized Assist Pump Development
3. Mylan Receives FDA Approval for Generic Version of Anticonvulsant Topamax(R) Sprinkle Capsules
4. AbbeyMoor Medical Receives Category I CPT(R) Code for The Spanner(TM) Prostatic Stent Procedure
5. Ortho Clinical Diagnostics Receives FDA Approval for First Anti-HIV 1+2 Test for Use on Random Access, Integrated Laboratory Testing System
6. Prime Therapeutics Receives 2010 TIPPS Certification for Adherence to High Transparency Standards
7. VIA Pharmaceuticals Receives Favorable Hearing Decision From NASDAQ
8. Otix Global Receives Nasdaq Bid Price Notice Deficiency
9. CVS/pharmacys Transportation Operations Receives Two National Safety Awards
10. Biostar Pharmaceuticals, Inc. Receives the Chinese Military Drug Administration Clearance to Begin Clinical Trial for Zushima Analgesic Aerosol Spray
11. Stereotaxis Receives Commitment to Increase and Extend Its Credit Facility With Silicon Valley Bank
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... -- Research and Markets has announced ... Applications, Technologies, Forecasts" report to their offering. ... Smart Skin, Structural Health Monitoring, Composite Smart Structures, ... involves electronic and/or electrical components and circuits that ... such as vehicle bodies or conformally placed upon ...
(Date:6/24/2016)... India , June 24, 2016 ... Needles Market by Type (Standard Pen Needles, Safety Pen ... Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, ... by MarketsandMarkets, This report studies the market for the ... expected to reach USD 2.81 Billion by 2021 from ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... Forecast to 2022" report to their offering. ... the patients with kidney failure, it replaces the function of ... patient,s blood and thus the treatment helps to keep the ... balance. Increasing number of ESRD patients & ...
Breaking Medicine Technology:
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... On ... as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle ... honor of the city’s history as home to some of the world’s leading providers ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet ... product that was developed to enhance the health of felines. The formula is all-natural ... two main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews ...
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can now ... and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings ... The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand ... project," said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s ... within Final Cut Pro X . Simply select a ProHand generator and drag ...
Breaking Medicine News(10 mins):